Search results for " industry"
Article
Supply Chain Challenges for Single-Use Systems
…ident of Technical Communication and Regulatory Strategy at Pall about some of the issues facing the industry as companies look to SUS for biopharmaceutical manufacturing.
Global supply chain
…
Article
From Darwin to Recombinant Fc Multimers
Appropriately, in his opening statement, conference chairperson Joe Bertolini, R&D director from CSL Behring Australia, reflected on what has happened in the plasma fractionation industry during these…
Article
Remote Monitoring and Big Data Advance Upstream Automation
Throughout the pharma industry, not just in upstream bioprocessing, there is, adds Dorizon Navarro, life sciences industry consultant at Rockwell Automation, an explosion of the integration of multipl…
Article
Biopharma Advances Demand Specialized Expertise
Lively (PPD): Growing interest in biopharmaceutical drug development necessitates partnering between clients and contractors to increase industry capacity, breadth of capabilities, expertise, and the …
Article
The Importance of Process Intensification and PAT for Achieving Real-Time Release
Lee and Mark Lies
Process intensification is of broad interest in the biopharmaceutical industry because of its promise and potential to increase efficiency and t…
Article
Biopharma Seeks Balance
During the past 30 years that BioPharm International covered the biopharma market, the industry continually evolved thanks to advances in biology, genomics, and other sciences. The strategic shift by …
Article
The Future of Biopharma
The biopharmaceutical industry continues to evolve with expectations of a positive future. Much of this anticipation is driven by pressure for the next new thing, demand for better bioprocessing techn…
Article
Regulatory Challenges in the QbD Paradigm
With the dawn of the 21st century came the realization that changes must be made by both the pharmaceutical industry and regulatory authorities across the globe. These changes are necessitated by a pl…
Article
Bracing for a Future Wave of Advanced Therapies
Buoyed by the regulatory approval of several cell and gene therapy (CGT) products for difficult-to-treat diseases, the US biopharma industry is now bracing for a new wave of CGTs in the near future as…
Article
Innovation vs. Capacity: How CMOs Compete
By Jim Miller
While industry participants and observers talk about the “CMO industry,” they know that it is not an undifferentiated mass of manufacturers. The contract and manufacturing organizati…